EXEL — Exelixis Inc.

Ownership history in BB BIOTECH AG  ·  4 quarters on record

This page tracks every 13F SEC filing in which BB BIOTECH AG reported a position in Exelixis Inc. (EXEL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.79% (2018 Q4)
Avg. % of fund
1.36%
First filed
2018 Q2
Last filed
2019 Q1
Quarters held
4
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2019 Q1 UNCHANGED 2,835,000 — 0% 1.70% $67.5M $23.80
2018 Q4 ADDED 2,835,000 +50,000 +1.8% 1.79% $55.8M $19.67
2018 Q3 ADDED 2,785,000 +1,725,000 +162.7% 1.31% $49.4M $17.72
2018 Q2 INITIATED 1,060,000 — — 0.66% $22.8M —
% of Fund (quarterly)    EXEL price (monthly, adj. close)

Other funds also holding EXEL

As of 2025 Q4 — sorted by position size

Krensavage Asset Management, LLC 3Y 7Y 7.64% 13D Management LLC 3Y 7Y 6.28% Caligan Partners LP 3Y 5.6% Capital Impact Advisors, LLC 3Y 7Y 3.75% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.25% South Street Advisors LLC 3Y 7Y 2.5% Seven Fleet Capital Management LP 2.29% Post Resch Tallon Group Inc. 1.93% GLOBEFLEX CAPITAL L P 3Y 7Y 1.75% SAWGRASS ASSET MANAGEMENT LLC 3Y 7Y 1.65%
← Back to BB BIOTECH AG Holdings